Chief Financial Officer Ben Taylor outlined the company’s integrated approach to AI-enabled drug discovery and development, recent portfolio decisions, partnership economics, and cash runway during a ...

Don't call Recursion Pharmaceuticals (NASDAQ: RXRX) a biotech company. Its management prefers the term "TechBio." While many have been skeptical about TechBio in the past, the reception is changing ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the 11 most popular AI penny stocks to buy now. On February 25, ...

We believe that Recursion RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is likely to beat expectations when it reports second-quarter 2024 results. The ...

Recursion Pharmaceuticals, Inc. ( RXRX) TD Cowen 46th Annual Health Care Conference March 2, 2026 9:50 AM EST All right. Good morning, again, for I see some familiar face in the last one, but thanks ...

Success for just one of Recursion's phase 2 programs could enable the stock to double within five years. However, the odds of success for phase 2 candidates aren't good. Risk-averse investors should ...